The study focuses on adults with Chronic Pancreatitis, a long‑lasting inflammation of the pancreas that often causes repeated episodes of abdominal pain and can lead to digestive problems. Participants will receive either the oral pain‑relieving drug Celecoxib, which belongs to a class of medicines known as NSAIDs, or a matching placebo. The goal is to find out whether the active medication can reduce pain, improve quality of life, lower the need for strong painkillers called opioids, and decrease signs of inflammation.

Each person will take the assigned tablet twice daily for about four months. During this time, they will complete a simple questionnaire called the Comprehensive Pain Assessment Tool Short Form (COMPAT‑SF) to record how much pain they feel, and another survey called the Short Form 36 (SF‑36) to evaluate overall well‑being. Blood samples will be taken to measure a protein linked to inflammation, known as high‑sensitivity C‑reactive protein (hs‑CRP), and the amount of opioid medication used will be expressed as oral morphine equivalents (OME). These checks are done at regular clinic visits, but no detailed technical procedures are required from the participants.

Safety is closely watched throughout the trial; doctors will look for any stomach irritation, bleeding, kidney changes, heart problems, or liver issues that might arise. Any unwanted effects are recorded and evaluated to ensure the treatment is well tolerated. The information gathered will help determine if the medication offers a meaningful benefit for people living with this condition.